Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

(2018) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy

(2018) Rudolf A. Werner et al.   MOLECULAR IMAGING AND BIOLOGY

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real‐World Data from the Spanish Tumor Registry (R‐GETNE)

(2018) Barbara Nuñez‐Valdovinos et al.   ONCOLOGIST

Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors

(2018) Dirk Walter et al.   Scientific Reports

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

(2017) Marianne Pavel et al.   NEUROENDOCRINOLOGY

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

(2017) Simron Singh et al.   NEUROENDOCRINOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular heterogeneity in breast cancer: State of the science and implications for patient care

(2017) Rachel E. Ellsworth et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Intratumor and Intertumor Heterogeneity in Melanoma

(2017) Tomasz M. Grzywa et al.   Translational Oncology

In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous

(2017) Mongkon Charoenpitakchai et al.   VIRCHOWS ARCHIV

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

(2016) Dieter Hörsch et al.   EUROPEAN JOURNAL OF CANCER

Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE

(2016) Christoph Wetz et al.   MOLECULAR IMAGING AND BIOLOGY

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

(2016) Rudolf A. Werner et al.   Oncotarget

[177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

(2016) Richard P. Baum et al.   Theranostics

Translational Implications of Tumor Heterogeneity

(2015) M. Jamal-Hanjani et al.   CLINICAL CANCER RESEARCH

Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

(2015) Amir Sabet et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status

(2015) L. Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The 2010 WHO Classification of Digestive Neuroendocrine Neoplasms: a Critical Appraisal four years after Its Introduction

(2014) G. Rindi et al.   ENDOCRINE PATHOLOGY

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

(2014) Vikas Prasad et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

(2014) Samer Ezziddin et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors

(2014) Ebrahim S. Delpassand et al.   PANCREAS

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

(2013) John J. Zaknun et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment with the Radiolabelled Somatostatin Analog177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

(2013) Maddalena Sansovini et al.   NEUROENDOCRINOLOGY

Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver

(2011) Zhaohai Yang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

(2010) Irene Virgolini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

(2009) Dik J. Kwekkeboom et al.   NEUROENDOCRINOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY